Antisense Oligonucleotide-mediated Suppression of Muscle Glycogen Synthase 1 Synthesis as an Approach for Substrate Reduction Therapy of Pompe Disease
Open Access
- 1 January 2014
- journal article
- Published by Elsevier in Molecular Therapy Nucleic Acids
- Vol. 3 (10) , e206
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- The emerging phenotype of long-term survivors with infantile Pompe diseaseGenetics in Medicine, 2012
- Morpholinos and their peptide conjugates: Therapeutic promise and challenge for Duchenne muscular dystrophyBiochimica et Biophysica Acta (BBA) - Biomembranes, 2010
- A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1Blood, 2010
- Restoration of muscle functionality by genetic suppression of glycogen synthesis in a murine model of Pompe diseaseHuman Molecular Genetics, 2009
- Pompe's diseaseThe Lancet, 2008
- Ability of Adeno-Associated Virus Serotype 8-Mediated Hepatic Expression of Acid α-Glucosidase to Correct the Biochemical and Motor Function Deficits of Presymptomatic and Symptomatic Pompe MiceHuman Gene Therapy, 2008
- Correction of ClC-1 splicing eliminates chloride channelopathy and myotonia in mouse models of myotonic dystrophyJournal of Clinical Investigation, 2007
- Glycogen storage disease types I and II: Treatment updatesJournal of Inherited Metabolic Disease, 2007
- Recombinant human acid α-glucosidaseNeurology, 2007
- Morphological changes in muscle tissue of patients with infantile Pompe's disease receiving enzyme replacement therapyMuscle & Nerve, 2003